Waldenstrom Macroglobulinemia
"Waldenstrom Macroglobulinemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
| Descriptor ID |
D008258
|
| MeSH Number(s) |
C04.557.595.925 C14.907.454.960 C15.378.147.780.925 C15.378.463.515.960 C15.604.515.925 C20.683.780.925
|
| Concept/Terms |
Waldenstrom Macroglobulinemia- Waldenstrom Macroglobulinemia
- Macroglobulinemia, Waldenstrom
- Lymphoma, Lymphoplasmacytoid
- Lymphomas, Lymphoplasmacytoid
- Lymphoplasmacytoid Lymphoma
- Lymphoplasmacytoid Lymphomas
- Macroglobulinemia
- Waldenstrom's Macroglobulinemia
- Macroglobulinemia, Waldenstrom's
- Waldenstroms Macroglobulinemia
- Waldenstrom's Macroglobulinaemia
- Macroglobulinaemia, Waldenstrom's
- Waldenstrom Macroglobulinaemia
- Waldenstroms Macroglobulinaemia
- Lymphoma, Lymphocytic, Plasmacytoid
- Primary Macroglobulinemia
- Macroglobulinemia, Primary
Familial Waldenstrom's Macroglobulinaemia- Familial Waldenstrom's Macroglobulinaemia
- Familial Waldenstrom Macroglobulinaemia
- Familial Waldenstroms Macroglobulinaemia
- Macroglobulinaemia, Familial Waldenstrom's
- Waldenstrom's Macroglobulinaemia, Familial
|
Below are MeSH descriptors whose meaning is more general than "Waldenstrom Macroglobulinemia".
Below are MeSH descriptors whose meaning is more specific than "Waldenstrom Macroglobulinemia".
This graph shows the total number of publications written about "Waldenstrom Macroglobulinemia" by people in this website by year, and whether "Waldenstrom Macroglobulinemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 1 | 6 |
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 2001 | 4 | 0 | 4 |
| 2002 | 1 | 1 | 2 |
| 2003 | 6 | 0 | 6 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 0 | 2 |
| 2014 | 7 | 1 | 8 |
| 2015 | 12 | 0 | 12 |
| 2016 | 20 | 1 | 21 |
| 2017 | 7 | 0 | 7 |
| 2018 | 24 | 0 | 24 |
| 2019 | 11 | 0 | 11 |
| 2020 | 15 | 0 | 15 |
| 2021 | 16 | 0 | 16 |
| 2022 | 7 | 0 | 7 |
| 2023 | 8 | 0 | 8 |
| 2024 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Waldenstrom Macroglobulinemia" by people in Profiles.
-
From the archives of MD Anderson Cancer Center: Composite mantle cell lymphoma and lymphoplasmacytic lymphoma involving bone marrow at presentation. Ann Diagn Pathol. 2024 Dec; 73:152372.
-
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat Commun. 2024 Aug 11; 15(1):6874.
-
Simplified Risk Stratification Model for Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42(21):2527-2536.
-
Optimizing BTK Inhibition in Waldenstr?m Macroglobulinemia. J Natl Compr Canc Netw. 2024 05; 22(4).
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 04 09; 8(7):1639-1650.
-
Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review. Leuk Lymphoma. 2024 Jul; 65(7):943-949.
-
Waldenstr?m Macroglobulinemia: Targeted Agents Taking Center Stage. Drugs. 2024 Jan; 84(1):17-25.
-
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr?m Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023 Nov 20; 41(33):5099-5106.
-
Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
-
Waldenstr?m Macroglobulinemia: A Myriad of Effective Treatment Options, but Still Work to be Done. Hematol Oncol Clin North Am. 2023 08; 37(4):xiii-xiv.